Biocept has appointed David Moskowitz as vice president of strategy and corporate communications. Prior to filling this newly created position at Biocept, Moskowitz was vice president of investor relations at Trovagene. He also worked as director of equity research at Caris & Co. and as head of healthcare research at Friedman Billings Ramsey. During his tenure in the financial services industry, Moskowitz held analyst positions at UBS Warburg and Roth Capital Partners, and has performed strategic advisory work for several emerging biopharmaceutical and molecular diagnostics companies.
Matthew Meyer and Noah Nasser
Counsyl has appointed Matthew Meyer as senior vice president of corporate development and Noah Nasser as vice president of women's health sales. Meyer joins Counsyl from CareDx, where he served as chief business officer. He is also an attorney who has worked at Pfizer, and as general counsel at Cerimon Pharmaceuticals and Draeger Medical Systems. Meyer has also held commercial roles at Allscripts and Novartis in Switzerland. Nasser joins Counsyl from AltheaDx, where he commercialized testing for pharmacogenetics. Prior to his post at AltheaDx, he served as the global sales leader for Verinata Health, an Illumina company. Before the acquisition of the company by Illumina in 2013, Nasser was Verinata's vice president of sales and market development.
AltheaDx has appointed Andrew Jackson as CFO. Jackson joins AltheaDx from Celladon, where he served as CFO and principal accounting officer. Prior to Celladon, he held senior finance positions at various life science and technology companies where he had experience with mergers and acquisitions, treasury management, capital and debt financing, and financial planning.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.